V-CHECK
Reliable and affordable in vitro diagnosis test for early detection of women's disease.
Fundraising Status
Series A
Fundraising Target: 4M
Schedule:
For Series B in Q3, 2023
Revenue (USD)
2022: 34K
2023 Target: 350K
Competitors
DotLab
Endodiag
US Objective
Expected Results
Fundraising
Seeking for Business Partners
Seeking for Strategic Investors
Specific Organizations/VCs to Engage
Quest
Mayo clinic
ACA plan
Private insurance company with women's health coverage
Company Details
Company description
V-CHECK INC is a Taiwan-based Med-tech company that specializes in developing innovative diagnostic technology for women's health. Since its inception in 2017, the company has been dedicated to provide reliable and cost-effective in vitro detection products for women's diseases, particularly for those without sensitive biomarkers for early diagnosis.
Core Technology
V-CHECK's team has extensive experience in high-throughput biomarker screening technology and is capable of designing testing platforms that cater to patients' needs and clinical settings.
V-CHECK's team is highly skilled in the manufacturing of various immunoassay testing platforms and reagents under the ISO13485 quality system standard for IVD products. This ensures that V-CHECK made products are reliable with good quality.
One pager poster_V CHECK.pdfTeam Members
You can meet her in person:
04/27-28 Maryland Spinoff
5/1-4 SelectUSA Summit (Maryland)
Sophia Lin, Director, Clinical & Regulatory Affairs
You can meet her in person:
04/27-28 Maryland Spinoff
5/1-4 SelectUSA Summit (Maryland)